Drug intelligence / Profile preview

GPC20X

Development stage: Preclinical
Lead developer: Exicure
Modality: Small Molecules
Administration: Intravenous

Overview

GPC20X is a preclinical-stage small molecule therapeutic being developed by GPCR Therapeutics USA. It is designed for the treatment of solid tumors as an immuno-oncology (I/O) therapy. The drug's mechanism involves targeting the C-X-C chemokine receptor type 4 (CXCR4) and a second G protein-coupled receptor (GPCR) as part of a heteromer complex (referred to as GPCRx2). By modulating these GPCR interactions, GPC20X aims to overcome the immunosuppressive tumor microenvironment and enhance the efficacy of cancer treatments.

Targets

MRGPRX2 (Mas-related G-protein Coupled Receptor X2)CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on GPC20X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPC20X.

Explore the full profile